Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2025 07:00 ET | Source: KSQ

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
March 05, 2025 07:00 ET | Source: KSQ

KSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of Directors

KSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of Directors
October 22, 2024 07:00 ET | Source: KSQ

KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors

KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
October 08, 2024 07:00 ET | Source: KSQ

KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer

KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
September 24, 2024 07:00 ET | Source: KSQ

KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy

KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
June 12, 2024 07:00 ET | Source: KSQ

KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
March 21, 2023 08:02 ET | Source: KuicK Research

Tumor Infiltrating Lymphocyte TIL Therapy Market Size Clinical Trials Companies Insight

Delhi, March 21, 2023 (GLOBE NEWSWIRE) -- Tumor infiltrating lymphocyte (TIL) therapy is an emerging field in cancer immunotherapy. As researchers all over the world are conducting clinical trials...
October 06, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...